1. Agmatine Protects Against the Progression of Sepsis Through the Imidazoline I2 Receptor-Ribosomal S6 Kinase 2-Nuclear Factor-κB Signaling Pathway.
- Author
-
Li, Xuanfei, Zhu, Junyu, Tian, Lixing, Ma, Xiaoyuan, Fan, Xia, Luo, Li, Yu, Jing, Sun, Yu, Yang, Xue, Tang, Wanqi, Ma, Wei, Yan, Jun, Xu, Xiang, and Liang, Huaping
- Subjects
- *
MITOGEN-activated protein kinase kinase , *AGMATINE , *MACROPHAGE inflammatory proteins , *APACHE (Disease classification system) , *IMIDAZOLINES , *NITRIC-oxide synthases , *DRUG receptors , *DISEASE progression , *RESEARCH , *MONONUCLEAR leukocytes , *CELL culture , *ANIMAL experimentation , *RESEARCH methodology , *ORGANIC compounds , *MACROPHAGES , *EVALUATION research , *MEDICAL cooperation , *SEPSIS , *CELLULAR signal transduction , *COMPARATIVE studies , *DNA-binding proteins , *TRANSFERASES , *MICE - Abstract
Objectives: The knowledge that agmatine is found in the human body has existed for several years; however, its role in sepsis has not yet been studied. In the present study, we investigate the role of agmatine in the progression and treatment of sepsis.Design: Clinical/laboratory investigations.Setting: Medical centers/University-based research laboratory.Subjects: Elective ICU patients with severe sepsis and healthy volunteers; C57BL/6 mice weighing 18-22 g.Interventions: Serum agmatine level and its associations with inflammatory markers were assessed in patients with sepsis. Agmatine was administered intraperitoneally to mice before a lipopolysaccharide challenge. Human peripheral blood mononuclear cells and murine macrophages were pretreated with agmatine followed by lipopolysaccharide stimulation.Measurements and Main Results: Serum agmatine levels were significantly decreased in patients with sepsis and lipopolysaccharide-induced mice, and correlated with Acute Physiology and Chronic Health Evaluation II score, procalcitonin, tumor necrosis factor-α, and interleukin-6 levels. In a therapeutic experiment, exogenous agmatine attenuated the cytokine production of peripheral blood mononuclear cells from patients with sepsis and healthy controls. Agmatine also exerted a significant beneficial effect in the inflammatory response and organ damage and reduced the death rate in lipopolysaccharide-induced mice. Imidazoline I2 receptor agonist 2-benzofuran-2-yl blocked the pharmacological action of agmatine; whereas, other imidazoline receptor ligands did not. Furthermore, agmatine significantly impaired the inflammatory response by inactivating nuclear factor-κB, but not protein 38 mitogen-activated protein kinase, c-Jun N-terminal kinase, extracellular signal-regulated kinase, and inducible nitric oxide synthase signaling in macrophages. Activation of imidazoline I2 receptor or knockdown of ribosomal S6 kinase 2 counteracted the effects of agmatine on phosphorylation and degradation of inhibitor of nuclear factor-κBα.Conclusions: Endogenous agmatine metabolism correlated with the progression of sepsis. Supplemental exogenous agmatine could ameliorate the lipopolysaccharide-induced systemic inflammatory responses and multiple organ injuries through the imidazoline I2 receptor-ribosomal S6 kinase 2-nuclear factor-κB pathway. Agmatine could be used as both a clinical biomarker and a promising pharmaconutrient in patients with severe sepsis. [ABSTRACT FROM AUTHOR]- Published
- 2020
- Full Text
- View/download PDF